We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Emerging threat of triazole-resistant Aspergillus fumigatus.
- Authors
Rybak, Jeffrey M; Fortwendel, Jarrod R; Rogers, P David
- Abstract
Invasive aspergillosis is a leading cause of morbidity and mortality among immunocompromised populations and is predicted to cause more than 200 000 life-threatening infections each year. Aspergillus fumigatus is the most prevalent pathogen isolated from patients with invasive aspergillosis, accounting for more than 60% of all cases. Currently, the only antifungal agents available with consistent activity against A. fumigatus are the mould-active triazoles and amphotericin B, of which the triazoles commonly represent both front-line and salvage therapeutic options. Unfortunately, the treatment of infections caused by A. fumigatus has recently been further complicated by the global emergence of triazole resistance among both clinical and environmental isolates. Mutations in the A. fumigatus sterol-demethylase gene cyp51A, overexpression of cyp51A and overexpression of efflux pump genes are all known to contribute to resistance, yet much of the triazole resistance among A. fumigatus still remains unexplained. Also lacking is clinical experience with therapeutic options for the treatment of triazole-resistant A. fumigatus infections and mortality associated with these infections remains unacceptably high. Thus, further research is greatly needed to both better understand the emerging threat of triazole-resistant A. fumigatus and to develop novel therapeutic strategies to combat these resistant infections.
- Subjects
TRIAZOLES; ASPERGILLUS fumigatus; MYCOSES; ASPERGILLUS; AMADORI compounds
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 2019, Vol 74, Issue 4, p835
- ISSN
0305-7453
- Publication type
journal article
- DOI
10.1093/jac/dky517